• Berberine hydrochloride: Gut–Bone Research Workflows

  2026-08-24

  Berberine hydrochloride enables integrated gut–bone, metabolic, and cell-death studies through controlled exposure, microbiome profiling, immune phenotyping, and organoid validation. This practical guide translates a 2026 tuft-cell study into reproducible workflows while addressing solubility, vehicle effects, and cross-model interpretation.

• PYR-41 E1 Inhibition: Reliable Cell Assays

  2026-08-24

  This scenario-driven guide shows how PYR-41, inhibitor of Ubiquitin-Activating Enzyme E1 (SKU B1492), can help researchers interpret viability, proliferation, cytotoxicity, and inflammatory signaling assays. It emphasizes solvent controls, dose-resolved designs, protein-stability readouts, and the limitations of translating E1 inhibition across models.

• Live-Dead Bacterial Staining Kit for Nanomaterials

  2026-08-23

  The Live-Dead Bacterial Staining Kit provides a membrane-based bacterial viability assay for testing antibacterial nanomaterials. This article explains how to interpret NucGreen and EthD-III signals mechanistically, using Fe3O4@ZIF-8 research as a case study while addressing assay limitations.

• Sulfo-NHS-SS-Biotin: Cleavable Surface Labeling

  2026-08-22

  Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for reversible protein labeling and surface-protein workflows. Its sulfo-NHS ester targets primary amines, while its disulfide spacer supports reduction-based label removal and avidin/streptavidin affinity chromatography.

• Cefiderocol Against Resistant European Non-Fermenters

  2026-08-22

  This reference study provides a large, direct in vitro comparison of cefiderocol with recent β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Its findings support early, parallel susceptibility testing while also linking cefiderocol resistance to acquired β-lactamases and changes involving siderophore-iron transport components.

• Exo1 and the Next Logic of Membrane-Traffic Biology

  2026-08-21

  Exo1 offers an acute, mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytosis. This thought-leadership perspective connects that tool to tumor extracellular vesicle research while distinguishing mechanistic validation from therapeutic claims.

• α-Linolenic Acid Research Workflows

  2026-08-20

  Build reproducible ALA experiments for lipid flux, cardiovascular signaling, inflammation, and cancer models with practical dosing and handling guidance. The workflow also shows how findings from an arachidonic acid vaccination study can inform—but not substitute for—careful α-Linolenic Acid immune-assay design.

• Cytochalasin D: Actin Control for Translational Research

  2026-08-20

  Cytochalasin D is more than a cytoskeletal perturbagen: it is a mechanistic tool for testing how actin dynamics influence cell-cycle control, cancer phenotypes, viral processes, and nanoparticle uptake. This article connects its established biology with translational strategy for researchers developing advanced cellular and ocular drug-delivery models.

• G-Quadruplexes Modulate TDP-43 Aggregation and Toxicity

  2026-08-19

  Oldani et al. show that RNA G-quadruplexes directly influence TDP-43 aggregation, intracellular distribution, and toxicity across biophysical and cellular models. The findings identify G-quadruplex populations as potential regulators of protein-misfolding stress, while also defining important limits for translating RNA-focused observations into therapeutic strategies.

• ERADECs: Hijacking ERAD to Degrade Membrane Proteins

  2026-08-19

  Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects transmembrane proteins to the ER E3 ligase SYVN1 for degradation. PD-L1-directed ERADECs showed sub-nanomolar activity and stronger tumor suppression than a clinical PD-L1 antibody benchmark, while desonide also enabled degradation of mutant HTT.

• GSK J4 HCl Workflow for JMJD3 Studies

  2026-08-18

  GSK J4 HCl supports cell-based studies of JMJD3, H3K27 methylation, inflammatory signaling, and tumor biology. This practical guide connects dose planning, chromatin readouts, and troubleshooting to a decidual CXCL10 research model while clearly separating established evidence from workflow recommendations.

• 7ACC2 and the Lactate–Immunity Axis in Cancer

  2026-08-18

  7ACC2 offers a powerful way to interrogate how MCT1-dependent lactate flux and mitochondrial pyruvate transport shape tumor metabolism, radiosensitization, and potential immunometabolic crosstalk. This article connects its preclinical pharmacology with the 25-hydroxycholesterol–AMPK–STAT6 macrophage pathway while defining the experiments needed to distinguish established evidence from translational hypotheses.

• α-Amanitin A4548: Reliable Assay Design

  2026-08-17

  A scenario-based guide to using α-Amanitin (SKU A4548) for RNA polymerase II inhibition, transcriptional regulation research, and cell-based viability studies. It connects mechanism, protocol parameters, data interpretation, and practical product-selection criteria to improve assay reproducibility.

• Early Life Adversity, Oxytocin, and Defensive Behavior

  2026-08-17

  A 2026 Communications Biology study shows that social deprivation during a defined postnatal period weakens looming-evoked innate defensive behavior in mice through impaired oxytocin signaling in the superior colliculus. The work connects early adversity to a specific hypothalamus–midbrain circuit and reports that intranasal oxytocin can ameliorate the behavioral deficit, while also identifying important limits for translation.

• EZ Cap™ OVA mRNA: A Delivery-First Guide

  2026-08-16

  Explore how EZ Cap™ OVA mRNA supports controlled antigen expression, immune response immunogen studies, and vaccine development research. This delivery-first guide explains Cap 1 biology, assay design, and how low-inflammatory lipid nanoparticle findings can inform—but not replace—experimental validation.

8111 records 1/541 page Next 12345 下5页 Last page